```html

Zollinger‑Ellison‑Associated Gastritis

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine tumor condition that produces excessive amounts of the hormone gastrin. The high gastrin levels stimulate the stomach’s parietal cells to secrete large volumes of gastric acid, which can erode the gastric lining and cause gastritis—inflammation of the stomach lining. When gastritis is directly linked to the acid hypersecretion of ZES, it is referred to as Zollinger‑Ellison‑associated gastritis.

Who it affects: ZES can occur at any age but is most commonly diagnosed in adults aged 30–60. There is no strong gender predilection, although some series report a slight male predominance (≈55%).

Prevalence: Gastrin‑producing tumors (gastrinomas) are estimated to occur in about 1–3 per million people per year. Roughly 20–30% of patients with gastrinomas develop ZES, and of those, >80% will have gastritis secondary to acid hypersecretion.

Because the condition is rare, many patients are initially misdiagnosed with peptic ulcer disease or ordinary gastritis, delaying proper treatment. Early recognition is essential to prevent complications such as ulcer perforation, bleeding, and, in some cases, gastric adenocarcinoma.

Symptoms

The symptoms of Zollinger‑Ellison‑associated gastritis result from the combination of excessive gastric acid and the inflammatory response of the stomach lining. Not every patient experiences all of them.

• Abdominal pain – Burning or gnawing pain, often described as “epigastric” (upper central abdomen). The pain may improve briefly after eating (duodenal ulcer pattern) or worsen (gastric ulcer pattern).
• Heartburn / gastro‑esophageal reflux – Persistent acid reflux, especially after meals.
• Upper‑GI bleeding – Hematemesis (vomiting blood), melena (black/tarry stools), or occult bleeding causing iron‑deficiency anemia.
• Diarrhea – Occurs in up to 40% of ZES patients due to acid inactivation of pancreatic enzymes and bile salts.
• Nausea & vomiting – May be intermittent; vomiting can be coffee‑ground if bleeding is present.
• Weight loss – From malabsorption, chronic diarrhea, or pain‑related reduced intake.
• Frequent ulcers – Multiple duodenal or gastric ulcers that are refractory to standard therapy.
• Severe acid reflux symptoms – Chronic cough, hoarseness, or throat irritation.
• Refractory or recurrent gastritis – Inflammation that persists despite conventional anti‑acid treatment.

Causes and Risk Factors

Primary cause

The underlying driver is a gastrin‑secreting neuroendocrine tumor (gastrinoma), most often located in the pancreas or duodenum. The tumor may be:

• Isolated (sporadic) – ~70% of cases.
• Part of Multiple Endocrine Neoplasia type 1 (MEN‑1) – ~25% of cases; patients with MEN‑1 have mutations in the MEN1 gene, predisposing them to several endocrine tumors, including gastrinomas.

Risk factors

• Family history of MEN‑1 or known gastrinomas.
• Genetic mutations in MEN1 or AIP genes.
• History of chronic gastritis or H. pylori infection – while not causal, they can exacerbate ulcer symptoms.
• Smoking and heavy alcohol use – increase gastric acid secretion and ulcer risk.
• Age >30 years – most gastrinomas are diagnosed after this age.

Diagnosis

Diagnosing Zollinger‑Ellison‑associated gastritis involves confirming hypergastrinemia, ruling out other causes of high gastrin, and identifying the gastrinoma.

Laboratory tests

• Fasting serum gastrin level – Levels >1000 pg/mL are highly suggestive; values 200–1000 pg/mL require further testing.
• Secretin stimulation test – Intravenous secretin paradoxically raises gastrin >120 pg/mL in ZES but not in other conditions.
• Basic metabolic panel – To assess electrolyte disturbances from vomiting or diarrhea.
• Complete blood count – Detects anemia from chronic bleeding.

Imaging studies

• Endoscopic ultrasound (EUS) – High‑resolution imaging for small pancreatic/duodenal lesions.
• Multiphasic contrast CT or MRI – Detects larger tumors and metastases (especially liver).
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – Gold standard for locating neuroendocrine tumors because most gastrinomas express somatostatin receptors.
• Upper endoscopy (EGD) – Visualizes gastritis, ulcers, and allows biopsies to rule out H. pylori or malignancy.

Diagnostic criteria (per NIH Consensus)

1. Fasting gastrin >1000 pg/mL OR >200 pg/mL with a positive secretin test.
2. Imaging that identifies a gastrinoma (or multiple lesions in MEN‑1).
3. Exclusion of other causes of hypergastrinemia (e.g., chronic atrophic gastritis, PPI use).

Treatment Options

Management targets two goals: (1) control gastric acid hypersecretion and (2) eradicate or control the gastrinoma.

Acid‑suppression therapy (first line)

• Proton pump inhibitors (PPIs) – High‑dose omeprazole 60–120 mg daily, esomeprazole 40–80 mg, or pantoprazole 80–160 mg. PPIs are the most effective at reducing acid output.
• Potassium‑competitive acid blockers (P‑CABs) – Vonoprazan (available in some countries) provides rapid, profound acid suppression and may be used when PPIs are insufficient.

Acid suppression is usually continued long‑term; dose adjustments are based on symptom control and ulcer healing on repeat endoscopy.

Tumor‑directed therapy

• Surgical resection – Curative for localized gastrinomas; enucleation or pancreaticoduodenectomy depending on size and location.
• Somatostatin analogues – Octreotide or lanreotide reduce gastrin secretion and may shrink metastatic disease.
• Targeted therapies – Everolimus or sunitinib for progressive metastatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for patients with high somatostatin‑receptor expression.
• Chemotherapy – Reserved for high‑grade or poorly differentiated neuroendocrine carcinomas.

Liver-directed treatments (for metastases)

• Radiofrequency ablation, hepatic artery embolization, or surgical metastasectomy.

Adjunctive measures

• Helicobacter pylori eradication – If present, treat with standard triple/quadruple therapy.
• Iron or vitamin B12 supplementation – For anemia due to chronic bleeding.
• Antidiarrheal agents – Loperamide for symptomatic control; octreotide may also reduce diarrheal output.

Living with Zollinger‑Ellison‑Associated Gastritis

Even with optimal medical and surgical treatment, many patients require lifelong management.

Medication adherence

• Take PPIs exactly as prescribed; never skip doses.
• Set reminders or use a pill‑box to avoid missed doses.
• Report any new side effects (e.g., persistent nausea, dizziness) to your provider.

Dietary & lifestyle tips

• Meal timing: Small, frequent meals reduce gastric acid spikes.
• Avoid irritants: Caffeine, alcohol, carbonated drinks, and very spicy foods can worsen symptoms.
• Stay hydrated: Especially important if you have diarrhea.
• Limit NSAIDs and aspirin: These drugs further damage the gastric mucosa.
• Quit smoking: Smoking increases acid secretion and impairs ulcer healing.

Monitoring & follow‑up

• Endoscopic surveillance every 1–2 years to assess ulcer healing and detect dysplasia.
• Serial gastrin levels every 6–12 months to monitor tumor activity.
• Imaging (CT/MRI or DOTATATE PET) annually for patients with known metastases.
• Annual bone density testing if on prolonged high‑dose PPIs (risk of reduced calcium absorption).

Psychosocial support

Living with a rare chronic condition can be stressful. Consider:

• Joining a support group (e.g., NET (Neuroendocrine Tumor) patient forums).
• Consulting a mental‑health professional for anxiety or depression.
• Utilizing patient‑education resources from reputable organizations such as the CDC and Mayo Clinic.

Prevention

Because the primary cause is a tumor, true primary prevention is limited. However, you can reduce secondary risk factors and complications:

• Screen high‑risk individuals: People with known MEN‑1 mutations should undergo periodic gastrin level checks and imaging per endocrinology guidelines.
• Avoid chronic PPI overuse without indication: Paradoxically, long‑term PPI use can cause hypergastrinemia, which may mask early ZES.
• Eradicate H. pylori infection promptly; it reduces additive ulcer risk.
• Maintain a healthy weight and minimize alcohol consumption to lower overall gastrointestinal stress.

Complications

If left untreated or inadequately controlled, Zollinger‑Ellison‑associated gastritis may lead to:

• Recurrent or perforated peptic ulcers – Can cause peritonitis, requiring emergency surgery.
• Severe upper‑GI bleeding – May result in anemia or hypovolemic shock.
• Duodenal or gastric strictures – From chronic inflammation and scarring.
• Electrolyte imbalances – Chronic vomiting or diarrhea can cause hypokalemia, metabolic alkalosis.
• Malabsorption and nutritional deficiencies – Due to inactivation of pancreatic enzymes and bile salts.
• Gastric adenocarcinoma – Long‑standing hyperacidic environment marginally increases cancer risk (estimated 2–5% over 10 years).
• Progression of metastatic gastrinoma – Leads to liver dysfunction, bowel obstruction, or paraneoplastic syndromes.

When to Seek Emergency Care

```